Hester Biosciences

Hester Biosciences reported a strong Q4 FY26 with standalone revenue growing 22% YoYCurrent reported value: 22% YoY. No comparable prior figure is available in the source record. and PAT surging 174% YoYCurrent reported value: 174% YoY. No comparable prior figure is available in the source record., driven by a 41% YoYCurrent 41% YoY. Reported change: +41% YoY. jump in poultry healthcare revenue. The poultry segment benefited from deeper market penetration and the launch of H9N2 avian influenza vaccine. Animal healthcare faced tender delays but improved in Q4 with 6.3 croreCurrent 6.3 crore. Reported change: N/A. PPR doses supplied. Consolidated revenue grew 22% YoYCurrent reported value: 22% YoY. No comparable prior figure is available in the source record. in Q4 and 7% for the full year, while PAT nearly doubled. Management expects animal healthcare to recover from Q1 FY27 and aims for a 50:50 revenue mix between poultry and animal health. Risks include tender timing volatility and rising raw material costs.